Actively Recruiting
Randomized Trial Comparing ASTX727 and Venetoclax With or Without Enasidenib for Older Adults With IDH2 Mutant Acute Myeloid Leukemia
Led by National Cancer Institute (NCI) · Updated on 2026-10-27
93
Participants Needed
138
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining ASTX727 and venetoclax with or without enasidenib in treating older adults newly diagnosed with acute myeloid leukemia AML who have a mutation in the IDH2 gene. This phase II trial aims to see if adding enasidenib to the usual treatment can improve outcomes by reducing measurable residual disease-negative complete remission rates in patients who are either older or unfit for standard therapy. Participants are randomly assigned to one of two treatment groups. One group receives oral ASTX727 daily on days 1-5 and venetoclax daily on days 1-28 of each 28-day cycle. The other group receives the same treatment plus oral enasidenib daily on days 1-28. Treatment cycles continue every 28 days unless disease progression or unacceptable side effects occur. Throughout the trial, blood samples, bone marrow aspirations, and biopsies are collected to monitor disease and treatment effects. During the study, participants undergo regular evaluations including blood tests and bone marrow procedures to assess remission status and measurable residual disease. After completing treatment, participants are followed monthly for the first year, then every two months in the second year, every three months in the third year, and every six months up to five years or until death. Researchers measure remission rates, survival outcomes, and adverse events to understand the treatments impact on AML with IDH2 mutation.
CONDITIONS
Brief Title
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here